Andre C Schuh

Aug 23, 2024 | digitalcommons.library.tmc.edu | Jenny Byrne |Stephane de Botton |Pau Montesinos |Andre C Schuh

This open-label, randomized, phase 3 trial (NCT02577406) compared enasidenib, an oral IDH2 (isocitrate dehydrogenase 2) inhibitor, with conventional care regimens (CCRs) in patients aged ≥60 years with late-stage, mutant-IDH2 acute myeloid leukemia (AML) relapsed/refractory (R/R) to 2 or 3 prior AML-directed therapies.